News

The FDA has approved Novartis' Pluvicto for a broader range of prostate cancer patients, significantly increasing the number of eligible patients. This approval is based on the Phase 3 PSMAfore trial, which demonstrated Pluvicto's efficacy and favorable safety profile in patients with PSMA-positive mCRPC who had previously received ARPI therapy.

Topcon Corporation, led by President and CEO Takashi Eto, announced a management buyout with investment from KKR & Co Inc and JIC Capital. The tender offer price of 3,300 yen per share represents a significant premium over Topcon's recent stock performance and is expected to commence around the end of July 2025.

BofA Securities analyst Robert F. Ohmes reiterated his Buy rating on Dollar General Corporation (DG) shares, citing several factors including increased trade-in activity, improved inventory levels, and a Back to Basics strategy aimed at enhancing efficiency. Despite Ohmes' positive outlook, DG shares traded lower on Friday.

SoftBank Group Corp. is considering investing over $1 trillion to establish AI-powered industrial parks across the U.S., aiming to address labor shortages and revolutionize manufacturing processes through autonomous robots. This ambitious project builds upon SoftBank's existing investments in AI infrastructure, including a $100 billion joint venture with OpenAI and Oracle Corp.

BofA Securities analyst Vivek Arya identified Analog Devices, NXP Semiconductors, and ON Semiconductor as his top picks for diversified semiconductor companies, citing their defensive nature and potential for growth in the second half of 2025. Despite lingering risks around tariffs and economic contraction, Arya believes these companies are well-positioned to outperform in a recovering market.